21
215380.KQ WOOJUNG BIO Inc
- Market cap
- KRW 34.1B
- P/E
- -
- P/B
- 1.28x
- ROE
- 23.8%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 215380.KQ undervalued?
Graham numberThe Graham number of WOOJUNG BIO Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WOOJUNG BIO Inc fundamental analysis
6 of 22 checks passedROE 2/2
High return on equity (23.8%), above 20%.
ROA 1/1
Return on assets (6.1%) is above the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-2,561.9%) is below the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 7.1% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (38.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.8x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.3x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
WOOJUNG BIO Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services. In addition, It offers …
Full company profileWOOJUNG BIO Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
WOOJUNG BIO Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.5B | 28.9B | 23.8B | 32.3B | 37.3B | 31.2B | 46.9B | 38.6B | 43.2B | 37.6B | 44.0B |
| Gross Profit | 6.77B | 5.88B | 7.00B | 9.79B | 5.30B | 5.88B | 6.73B | 6.29B | 12.7B | 10.1B | 14.2B |
| Operating Income | -68.4M | -2.44B | -3.46B | 642M | -5.31B | -3.53B | -3.37B | -6.27B | 2.32B | -3.65B | 820M |
| EBITDA | - | - | - | - | - | - | 5.18B | 2.49B | 7.66B | 1.12B | 12.5B |
| Net Income | 77.2M | -6.92B | -3.98B | 280M | -10.9B | -1.93B | -1.88B | -5.05B | 225M | -5.55B | 6.32B |
| EPS | 35 | -804 | -409 | 27 | -912 | -151 | -147 | -340 | 14 | -333 | 379 |
| Balance Sheet | |||||||||||
| Total Assets | 12.0B | 31.4B | 44.8B | 57.6B | 69.8B | 100B | 95.0B | 98.3B | 94.7B | 86.8B | 103B |
| Total Liabilities | 1.43B | 13.1B | 23.6B | 31.0B | 41.8B | 68.7B | 65.3B | 76.4B | 65.3B | 63.4B | 76.7B |
| Shareholders' Equity | 10.6B | 18.3B | 21.2B | 26.7B | 28.0B | 31.5B | 29.7B | 22.0B | 29.4B | 23.4B | 26.6B |
| Cash & Short-term Investments | 11.9B | 10.9B | 17.2B | 15.1B | 15.8B | 6.75B | 4.82B | 5.57B | 4.27B | 3.83B | 15.7B |
| Total Debt | - | - | 8.64B | 2.22B | 24.8B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.46B | -2.38B | -484M | 209M | -8.57B | 1.73B | 2.50B | -3.22B | -1.13B | -630M | - |
| Capital Expenditure | 1.33B | 1.24B | 4.67B | 2.16B | 15.8B | 36.7B | 11.4B | 887M | 310M | 259M | 34.0M |
| Free Cash Flow | - | - | - | - | -25.2B | -35.0B | -9.01B | -4.11B | -1.44B | -890M | - |
| Ratios | |||||||||||
| ROE | 0.7% | -37.8% | -18.8% | 1.0% | -38.8% | -6.1% | -6.3% | -23.0% | 0.8% | -23.7% | 23.8% |
| ROA | 0.6% | -22.0% | -8.9% | 0.5% | -15.6% | -1.9% | -2.0% | -5.1% | 0.2% | -6.4% | 6.1% |
| Net Profit Margin | 0.4% | -23.9% | -16.7% | 0.9% | -29.1% | -6.2% | -4.0% | -13.1% | 0.5% | -14.8% | 14.4% |
| Debt to Equity | - | - | 0.41x | 0.08x | 0.88x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
WOOJUNG BIO Inc dividends
WOOJUNG BIO Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Aug 6, 2019.
Who owns WOOJUNG BIO Inc
- Insiders 39.29%
- Institutions 0.00%
- Public & others 60.71%
- Shares outstanding 16.7M
- Free float 2.46M
WOOJUNG BIO Inc company profile
- Company name
- WOOJUNG BIO Inc
- Ticker
- 215380.KQ
- ISIN
- KR7215380007
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- Kolmar BioCluster, Hwaseong-si, South Korea
- Phone
- 82 3 1280 5200
- Website
- kolmarbiotech.com
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services. In addition, It offers construction and implementation, infection control, maintenance, laboratory and pharmaceutical equipment, and consumables and animal resourcing services. Kolmar BioTech, Inc. was formerly known as WOOJUNG BIO, Inc. and changed its name to Kolmar BioTech, Inc. in July 2026. The company was founded in 1989 and is based in Hwaseong-si, South Korea.
WOOJUNG BIO Inc management
1- ByungSeok MoonCEO & Director · born 1960